CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases

Cancer Cell. 2025 Oct 13;43(10):1937-1957.e11. doi: 10.1016/j.ccell.2025.07.007. Epub 2025 Aug 7.

Abstract

Bone metastases remain incurable and respond poorly to immune checkpoint blockade (ICB) therapy. The impact of neutrophil maturation in cancer, particularly in refractory tumors including bone metastases, is not well understood. Here, we observed the predominance of immature neutrophils in the bone metastasis microenvironment of both mouse models and cancer patients. Dickkopf1 (DKK1) induces an immature-like functional state in neutrophils, which exhibit robust immunosuppressive capabilities to inhibit anti-tumor response of CD8+ T cells. Mechanistically, the DKK1-CKAP4-STAT6 signaling pathway drives CHI3L3 expression, which is necessary for the immune suppression mediated by immature neutrophils in bone metastases. Moreover, blocking DKK1 promotes neutrophil maturation to improve the immune microenvironment, induces tumor shrinkage, and enhances ICB therapy response in multiple bone metastasis mouse models. These findings uncover a critical role for immature neutrophils in bone metastases and suggest a potential strategy for modulating neutrophils to improve cancer immunotherapy.

Keywords: CHI3L3; DKK1; bone metastases; cancer immunotherapy; immature neutrophils.

MeSH terms

  • Animals
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / immunology
  • Bone Neoplasms* / secondary
  • CD8-Positive T-Lymphocytes / immunology
  • Cell Line, Tumor
  • Female
  • Humans
  • Immune Checkpoint Inhibitors* / pharmacology
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Intercellular Signaling Peptides and Proteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Neutrophils* / immunology
  • Neutrophils* / metabolism
  • Signal Transduction
  • Tumor Microenvironment / immunology

Substances

  • Immune Checkpoint Inhibitors
  • Intercellular Signaling Peptides and Proteins